Pizotifen as an antidepressant

@article{Standal1977PizotifenAA,
  title={Pizotifen as an antidepressant},
  author={J E Standal},
  journal={Acta Psychiatrica Scandinavica},
  year={1977},
  volume={56}
}
  • J. Standal
  • Published 1 October 1977
  • Psychology, Medicine
  • Acta Psychiatrica Scandinavica
In a double‐blind study the therapeutic effect and tolerance of pizotifen was compared with placebo in 20 outpatients of both sexes suffering from light to moderate depression. Pizotifen seems to possess certain antidepressive effects in dosages of 4–10 mg daily. These properties, and the well‐documented effect of pizotifen in migraine, could make it an alternative in treating patients suffering from the often seen combination of vascular headache/depression. 

The central action of pizotifen

Results suggest that pizotifen strongly blocks the central postsynaptic serotonin receptors in mice, rats and rabbits, and is ineffective in classic tests for antidepressant activity.

A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action

The preclinical and clinical data suggest that trazodone acts as an antidepressant via antagonist action at 5-HT2/1C receptors, while fluoxetine likely acts as a antidepressant via inhibition of 5- HT uptake.

Effects of chronic treatment with antidepressants on aggressiveness induced by clonidine in mice

Experiments show that chronic, but not acute, administration of nisoxetine, a selective inhibitor of noradrenaline uptake, potentiates clonidine-induced aggressiveness, which seems to support the previous hypothesis that potentiation of clonazine-induced aggression is mediated by anα 1-adrenergic mechanism.

Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders

Clinical and preclinical observations suggest that the combination of highly selective 5-HT2A antagonists and SSRIs, as well as strategies to combine high-potency 5- HT2A receptor and5-HT transporter blockade in a single compound, offer the potential for therapeutic advances in a number of neuropsychiatric disorders.

A comparison of drugs versus placebo for the treatment of dysthymia.

Drugs are effective in the treatment of dysthymia with no differences between and within class of drugs and tricyclic antidepressants are more likely to cause adverse events and dropouts.

Chronic treatment with some atypical antidepressants increases the brain level of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rats

The results indicate that chronic administration of atypical antidepressants leads to activation of the central NA system, and corroborate the existence of a serotonergic-noradrenergic interaction, consisting of an inhibitory influence of serotonin on the noradrenaline system.

Drugs versus placebo for dysthymia.

Drugs are effective in the treatment of dysthymia with no differences between and within class of drugs and tricyclic antidepressants are more likely to cause adverse events and dropouts.

The effect of some new antidepressants on apomorphine‐induced hypothermia in mice

The effect of some new antidepressants is examined in this test, especially as some of them differ in their mechanism of action from imipramine‐like drugs.

References

SHOWING 1-6 OF 6 REFERENCES

CLINICAL TRIAL OF A NEW SEROTONIN ANTAGONIST, BC105, IN THE PREVENTION OF MIGRAINE

AgrIcultural Tractor Accidents-A Description ot Fourteen T tractor Accidents and a Comparison with Road Tramc Accidents, Brit.

The action of BC-105 in chronic schizophrenics with depression.

BC-105 a new antidepressant

  • Psychosomatics
  • 1969

BC-105 in the treatment of migraine

  • 1968

Die larvierte Depression . Briider Hollinek , Vienna . in chronic schizophrenics with depression

  • Curr . ther . Res .
  • 1969